Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A latin american survey

Highlights • In this COVID-19 context, there is an urgent necessity of sharing information to enable evidence-based decision making on the clinical management.• In LATAM, 60% of the experts had the possibility of monitoring their patients by telemedicine.• Most neurologists postpone magnetic resonance and laboratory blood tests delay is associated with the type of MS or NMOSD treatment.• Platform therapies, dimethyl-fumarate and natalizumab are considered safe options to initiate in naive patients.

• Publication year

  2020

• Venue

  Multiple Sclerosis and Related Disorders

• Publication date

  2020-06-20

• Fields of study

  Medicine, Sociology

• Identifiers
  DOI 10.1016/j.msard.2020.102310PMID 32590314PMCID 7837246
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Asymptomatic infection of COVID-19 and its challenge to epidemic prevention and control].

  2020cited by this paper
• Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

  2020cited by this paper
• Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

  2020cited by this paper
• Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.

  2020cited by this paper
• Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2

  2020cited by this paper
• Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge

  2020cited by this paper
• Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic

  2020cited by this paper
• The COVID-19 pandemic and the use of MS disease-modifying therapies

  2020cited by this paper
• The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

  2020cited by this paper
• Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.

  2020cited by this paper
• WHO Declares COVID-19 a Pandemic

  2020cited by this paper
• COVID-19 in Latin America: The implications of the first confirmed case in Brazil

  2020cited by this paper
• An update on the safety of treating relapsing-remitting multiple sclerosis

  2019cited by this paper
• Highly active multiple sclerosis: An update.

  2019cited by this paper
• Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis

  2019cited by this paper
• Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis.

  2019cited by this paper
• Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

  2019cited by this paper
• Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

  2019cited by this paper
• Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

  2019cited by this paper
• Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.

  2019cited by this paper
• Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study

  2018cited by this paper
• Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

  2018cited by this paper
• Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.

  2018cited by this paper
• Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients.

  2018cited by this paper
• Changes in the Multiple Sclerosis Treatment Paradigm. What Do We Do Now and What Were We Doing Before?

  2018cited by this paper
• Both cladribine and alemtuzumab may effect MS via B-cell depletion

  2017cited by this paper
• Both cladribine and alemtuzumab may effect MS via B-cell depletion

  2017cited by this paper
• Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder

  2017cited by this paper
• Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

  2016cited by this paper
• Summary of product characteristics

  2016cited by this paper
• Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients

  2016cited by this paper
• Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.

  2015influential reference
• Long‐term follow‐up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab

  2014cited by this paper
• Switching Therapies in Multiple Sclerosis

  2013influential reference
• Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: a case-control study.

  2013cited by this paper
• Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta

  2013cited by this paper
• Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

  2012cited by this paper
• Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus.

  2006cited by this paper

• Application and interpretation of core elements of the 2015 NMOSD diagnostic criteria in routine clinical practice

  2024cites this paper
• Argentinean consensus recommendations for the use of telemedicine in clinical practice in adult people with multiple sclerosis

  2022cites this paper
• Impact of COVID-19 Pandemic in Patients with Demyelinizing Diseases

  2022cites this paper
• Prevalence of coronavirus disease 2019 in patients with neuromyelitis optica in Isfahan, Iran, and a review on recent reports and literature

  2021cites this paper
• How the COVID-19 Pandemic has changed multiple sclerosis clinical practice: Results of a nationwide provider survey

  2021influential citation
• Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD

  2021cites this paper
• SARS-CoV-2 (COVID-19) en pacientes con algún grado de inmunosupresión

  2020cites this paper
• Impact of COVID-19 on people with physical disabilities: A rapid review

  2020cites this paper
• Experience of South American MS and/or NMOSD experts in practice during the COVID-19 pandemic: Focus on Telemedicine

  2020influential citation
• SARS-CoV-2 (COVID-19) in patients with some degree of immunosuppression

  2020cites this paper
• ARS-CoV-2 (COVID-19) in patients with some degree of mmunosuppression

  year unknowncites this paper